TNF-α基因-308G/A位点多态性与前列腺癌易感性关系的Meta分析_《中国循证医学杂志》

作者：

王莽原 ¹ , 韩振伟 ² , 刘嘉铭 ² ,  廖邦华 ²

1. 四川大学华西临床医学院（成都 610041）；2. 四川大学华西医院泌尿外科（成都 610041）;

关键词：

前列腺癌肿瘤坏死因子-α（TNF-α）多态性 Meta分析

DOI：

10.7507/1672-2531.20120160

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　采用Meta分析的方法评价TNF-α基因中–308G/A位点多态性和前列腺癌易感性之间的关系，为进一步阐明前列腺癌发病的分子机制及筛查前列腺癌高风险人群提供参考。
方法　计算机检索PubMed（1950～2011）、EMbase（1990～2011）、CNKI、CBM、VIP和WanFang Data，按照纳入与排除标准筛出关于TNF-α-308位点多态性与前列腺癌相关性的病例-对照研究或队列研究，检索时限均为从建库至2012年1月。在提取数据和评价纳入研究的方法学质量后，采用RevMan 5.1.4 和Stata 11.0 软件进行统计分析。
结果　共纳入11个研究，4 919例前列腺癌患者，5 210例健康对照。Meta分析结果显示：① 前列腺癌组与对照组中基因型AA vs. GG［OR=0.92，95%CI（0.71，1.20），P=0.55］、GA vs. GG［OR=1.11，95%CI（0.90，1.37），P=0.33）、AA vs. GG + GA［OR=0.91，95%CI（0.70，1.18），P=0.47）、GA + AA vs. GG［OR=1.11，95%CI（0.90，1.36），P=0.33）、等位基因A vs. G［OR=1.07，95%CI（0.91，1.26），P=0.39］与前列腺癌易感性之间均无相关性；② 以人种为亚组进行分层分析，发现TNF-α–308位点的多样性在不同人种中也无明显相关性（P gt;0.05）。
结论　现有证据显示，TNF-α–308位点等位基因和基因型可能与前列腺癌易感性无关。由于纳入研究数量有限，上述结论尚需开展更多高质量、大样本的随机对照试验加以验证。

引用本文： 王莽原,韩振伟,刘嘉铭,廖邦华. TNF-α基因-308G/A位点多态性与前列腺癌易感性关系的Meta分析. 中国循证医学杂志, 2012, 12(8): 1030-1034. doi: 10.7507/1672-2531.20120160 复制

1.	American Cancer Society: Cancer facts & ﬁgures. American Cancer Society, Atlanta, 2009.
2.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3.	Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4.	Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5.	Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6.	Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7.	Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8.	Dufﬁeld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9.	Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10.	Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11.	Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12.	Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13.	Bouraoui Y, Ricote M, García-Tuñón I, et al. Proinﬂammatory cytokines and prostate speciﬁc antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14.	Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15.	Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16.	Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17.	OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18.	Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19.	Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20.	Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21.	Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22.	Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23.	Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24.	Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25.	Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26.	Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

1. American Cancer Society: Cancer facts & ﬁgures. American Cancer Society, Atlanta, 2009.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3. Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4. Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7. Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8. Dufﬁeld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11. Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12. Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13. Bouraoui Y, Ricote M, García-Tuñón I, et al. Proinﬂammatory cytokines and prostate speciﬁc antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15. Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16. Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17. OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18. Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19. Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21. Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22. Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24. Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

上一篇
我国示范乡镇卫生院基本药物循证评价与遴选之二十：人工流产
下一篇
编前寄语

《中国循证医学杂志》

TNF-α基因-308G/A位点多态性与前列腺癌易感性关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

TNF-α基因-308G/A位点多态性与前列腺癌易感性关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料